TABLE 3 Marine-Derived Antitumor Compounds Licensed for Development

Marine Source

Drug

Organism

Current Status

Sponge

Discodermolide

Discodermia dissoluta

To enter Phase I trials in 2002; licensed to Novartis

Isohomo-halichondrin B

Lissodendoryx sp.

Licensed to PharmaMar S.A.; in advanced preclinical trials

Bengamide

Jaspis sp.

Synthetic derivative licensed to Novartis; in clinical trials

Hemiasterlins A & B

Cymbastella sp.

Derivatives to enter clinical trials in 2002; licensed to Wyeth-Ayerst

Girolline

Pseudaxinyssa cantharella

Licensed to Rhone Poulenc

Bryozoan

Bryostatin 1

Bugula neritina

In Phase I/II clinical trials in U.S./Europe; U.S. National Cancer Institute (NCI) sponsored trials

tion of the resource (see Rosenthal, p. 91 in this report). In all cases, commercial development from natural populations of marine organisms must be sustainable if it is to make economic sense. Sustainability is one of the central challenges in further development of marine biotechnology, and it must be addressed before large-scale marine harvests can begin. Innovative approaches to partnerships between stakeholders can help to support access to marine resources and to ensure their development as sustainable assets. Agreements that include training and education of local populations can be particularly valuable for long-term resource sustainability.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement